Mitsutaka Osawa
Overview
Explore the profile of Mitsutaka Osawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang M, Zhang Z, Imamura M, Osawa M, Teraoka Y, Piotrowski J, et al.
J Hepatol
. 2021 Aug;
75(6):1335-1345.
PMID: 34363922
Background & Aims: HBV consists of 9 major genotypes (A to I), 1 minor strain (designated J) and multiple subtypes, which may be associated with different clinical characteristics. As only...
2.
Ma C, Imamura M, Talley D, Rolt A, Xu X, Wang A, et al.
Nat Microbiol
. 2020 Sep;
5(12):1532-1541.
PMID: 32868923
Fluoxazolevir is an aryloxazole-based entry inhibitor of hepatitis C virus (HCV). We show that fluoxazolevir inhibits fusion of HCV with hepatic cells by binding HCV envelope protein 1 to prevent...
3.
Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, et al.
Ther Adv Med Oncol
. 2020 Jun;
12:1758835920922051.
PMID: 32547646
Background: Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been...
4.
Cheng X, Uchida T, Xia Y, Umarova R, Liu C, Chen P, et al.
J Clin Invest
. 2020 Mar;
130(6):3205-3220.
PMID: 32163375
In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied...
5.
Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, et al.
J Med Virol
. 2019 Oct;
92(2):210-218.
PMID: 31584207
Ribavirin (RBV) induces nucleotide (nt) substitutions in hepatitis C virus (HCV) genome nonstructural (NS) regions. Although emergence of drug resistance-associated variants is associated with direct-acting antiviral treatment failure, the effect...
6.
Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, et al.
Clin J Gastroenterol
. 2019 Aug;
13(2):267-270.
PMID: 31463795
Although NS3/4 protease inhibitor glecaprevir (GLE) plus NS5A inhibitor pibrentasvir (PIB) therapy has a high efficacy for chronic hepatitis C virus (HCV)-infected patients with hemodialysis, some patients fail to respond...
7.
Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, et al.
J Gen Virol
. 2019 Jun;
100(7):1123-1131.
PMID: 31199224
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy for patients who acquired potent NS5A inhibitor resistance-associated variants...
8.
Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, et al.
Hepatol Commun
. 2019 Mar;
3(3):348-355.
PMID: 30859147
Although the effect of levocarnitine (L-carnitine) on hyperammonemia has been reported in patients with liver cirrhosis (LC), its effect on sarcopenia remains to be elucidated. We assessed the effects of...
9.
Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, et al.
J Gastroenterol
. 2018 Oct;
54(3):291-296.
PMID: 30334096
Background: Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy of the therapy for failures to prior direct-acting...
10.
Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, et al.
Hepatol Res
. 2018 Jul;
48(13):1118-1130.
PMID: 30030881
Aim: The aim of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) between 5-fluorouracil (5-FU)-based continuous infusion chemotherapy and low-dose cisplatin (CDDP) monotherapy...